GlassScriptPhysician profile
Kerim F Razack
NPI 1881688331
$2,504.67
in general payments reported to CMS, 2019-2025
20 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $35.49 · 2022: $209 · 2023: $893 · 2024: $1,032 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $387.80 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abiomed | $369.70 | 2024 | Impella |
| Inspire Medical Systems, INC. | $230.86 | 2023-2024 | Inspire |
| Mylan Specialty L.P. | $184.00 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.29 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $162.41 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Sunovion Pharmaceuticals INC. | $116.84 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $113.47 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $109.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $108.15 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $84.18 | 2023-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $75.48 | 2023-2024 | Recarbrio, Dificid, Zerbaxa |
| Philips North America LLC | $59.76 | 2024-2025 | Home Pi Undivided, (5091) Amd Und, (Ee0) Cc Others Undivided |
| Shionogi INC | $54.38 | 2023-2024 | Fetroja |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.58 | 2022-2024 | |
| Baxter Healthcare | $39.28 | 2023 | Hillrom - Life 2000 Ventilation System |
| Ceribell, INC. | $37.39 | 2024 | Pocket Eeg Device |
| Genzyme Corporation | $29.62 | 2024 | |
| Harmony Biosciences LLC | $20.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerim Razack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.